Results 261 to 270 of about 129,510 (314)

Current Challenges in Hemostasis and Advances in Particle‐Assisted Styptic Devices

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 2, 14 January 2026.
Here persistent limitations in hemostatic technologies are highlighted and cutting‐edge biomimetic, microparticle‐assisted, and nanoengineered systems with integrated drug delivery are showcased. Moreover, the article identifies fresh directions toward the next‐generation of multifunctional hemostatic devices with superior efficacy and accessibility ...
Daniele Baiocco   +4 more
wiley   +1 more source

A Robust Serum Proteomic Signature of the E2 Allele of Apolipoprotein E

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
This study expands a serum protein signature of the e2 allele of APOE using multiple proteomic platforms and UK Biobank replication. The signature supports the role of APOE in lipid regulation through apolipoproteins and inflammation and includes, among others, neutrophil secreted granule proteins CAMP, CTSG, DEFA3, and MPO that point to inhibition of ...
Paola Sebastiani   +20 more
wiley   +1 more source

Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET)

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.
ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi   +11 more
wiley   +1 more source

Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio‐Hermes Study participants

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) study participants may present with cognitive impairment who do not have brain amyloid deposits (Aβ−). Identifying predictive biomarkers for non‐amyloid‐related CI may provide better screening tests for trials seeking only CI Aβ+ participants and new therapy targets.
Richard C. Mohs   +11 more
wiley   +1 more source

Astrocyte–vascular interplay in Alzheimer's disease pathology: Novel insights into stage‐specific biomarkers and therapeutic targets

open access: yesAlzheimer's &Dementia, Volume 22, Issue 1, January 2026.
Abstract INTRODUCTION We examined how neurovascular and astrocytic response alter cognition in Alzheimer's disease (AD). METHODS Cognitive scores, biomarkers of AD and astrocytic activation, vascular factors, and brain structure data from 693 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants were analyzed using analysis of covariance ...
Zehu Sheng   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy